首页> 外文期刊>AIDS Research and Therapy >Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies
【24h】

Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies

机译:艾滋病毒治疗艾滋病毒治疗艾滋病毒的可接受性,动机和治愈前景,其医疗保健提供者在艾滋病毒治愈治疗中断研究中

获取原文
           

摘要

Analytical treatment interruptions (ATI) are commonly used clinical endpoints to assess interventions aimed at curing HIV or achieving antiretroviral therapy (ART)-free HIV remission. Understanding the acceptability of ATI amongst people living with HIV (PLHIV) and their HIV healthcare providers (HHP) is limited. Two online surveys for PLHIV and HHP assessed awareness and acceptability of ATI, and understanding of the prospect for HIV cure in the future. Responses were collected from July 2017–January 2018. A descriptive analysis was performed and similar questions across the two surveys were compared using χ squared test. 442 PLHIV and 144 HHP completed the survey. 105/400 (26%) PLHIV had ever interrupted ART, 8% of which were in a clinical trial. Altruistic motivations were drivers of participation of PLHIV in cure related research. 81/135 (60%) HHP would support their patients wishing to enrol in an HIV cure-focused trial, but fewer would promote and allow such participation (25% and 31% respectively). Compared to HHP, PLHIV were more likely to believe that an HIV cure would be achievable within 10?years (55% vs. 19%, p??0.001), had less awareness of ATI (46% vs. 62%, p??0.001) and were less likely to have had experience of either participation or enrolment in an ATI study (5% vs. 18%, p??0.001) PLHIV were more optimistic about the potential for HIV cure. HHP had more direct experience with HIV cure-focused studies. Educational strategies are required for both groups to increase understanding around ATIs in HIV cure research but should be tailored specifically to each group.
机译:分析治疗中断(ATI)通常是使用临床终点,以评估旨在固化艾滋病毒或实现抗逆转录病毒治疗(ART)-FREE HIV缓解的干预措施。了解与艾滋病毒(PLHIV)的人们和艾滋病毒医疗保健提供者(HHP)的人们的可接受性有限。两次在线调查为PLHIV和HHP评估了ATI的意识和可接受性,并对未来的艾滋病毒治愈前景的理解。从2017年7月至2018年1月收集了响应。使用χ平方试验进行了对描述性分析,并使用两种调查的类似问题。 442 PLHIV和144 HHP完成了调查。 105/400(26%)Plhiv曾被中断艺术,其中8%在临床试验中。利他主义的动机是PLHIV在治愈相关研究中的参与的驱动因素。 81/135(60%)HHP将支持他们希望注册艾滋病毒治愈的审判的患者,但较少将促进并允许此类参与(分别为25%和31%)。与HHP相比,Plhiv更有可能相信HIV治愈率将在10岁以下(55%对19%,P?<0.001),对ATI的认识较小(46%对62%,P ?<?0.001)并且不太可能在ATI研究中具有参与或注册的经验(5%对18%,P?<β001)Plhiv对HIV治愈的可能性更加乐观。 HHP与艾滋病毒的重点研究有更多直接的经验。两组群体需要教育策略,以增加艾滋病毒治愈研究中的atis对atis的理解,但应专门针对每组量身定制。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号